Blog

New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca.

This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

The collaboration is important for BenevolentAI as it comes with an upfront payment, development milestone payments and tiered royalties on future revenues.  But, more importantly, the spirit of this deal is different. Rather than a standard service provision agreement, this deal represents a true partnership: combining AstraZeneca’s world-leading disease area expertise and large diverse datasets together with our machine learning discovery and AI-enabled target ID capabilities.

AstraZeneca and BenevolentAI will work side by side in joint multidisciplinary teams, integrating working practices across data science, machine learning, respiratory and cardiovascular R&D, Target ID and precision medicine to break down traditional drug discovery boundaries and enable more efficient data-driven decision making. The combined AstraZeneca/BenevolentAI teams will incorporate proprietary data, tailor approaches to using that data, jointly interpret the results and then work together to identify targets that we hope will lead to new medicines.

Partnerships aren’t forged on paper. In all our interactions to date, AstraZeneca has proven to be open, progressive and committed to working together. Both companies share a common purpose and mindset in unlocking the power of scientific data to make more effective drugs for the people that need them and I’m incredibly excited to combine forces with them on targeting two critical disease areas that affect the lives of millions of people.

Joanna Shields, CEO

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
NeurIPS 2020: Meet the BenevolentAI team
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020